Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Long‐term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

Ruperto, Nicolino, Lovell, Daniel J., Quartier, Pierre, Paz, Eliana, Rubio‐Pérez, Nadina, Silva, Clovis A., Abud‐Mendoza, Carlos, Burgos‐Vargas, Ruben, Gerloni, Valeria, Melo‐Gomes, Jose A., Saad‐Magalhães, Claudia, Chavez‐Corrales, J., Huemer, Christian, Kivitz, Alan, Blanco, Francisco J., Foeldvari, Ivan, Hofer, Michael, Horneff, Gerd, Huppertz, Hans‐Iko, Job‐Deslandre, Chantal, Loy, Anna, Minden, Kirsten, Punaro, Marilynn, Nunez, Alejandro Flores, Sigal, Leonard H., Block, Alan J., Nys, Marleen, Martini, Alberto, Giannini, Edward H. · 2010 · Arthritis & Rheumatism

Abstract

Objective: We previously documented that abatacept was effective and safe in patients with juvenile idiopathic arthritis (JIA) who had not previously achieved a satisfactory clinical response with disease‐modifying antirheumatic drugs or tumor necrosis factor blockade. Here, we report results from the long‐term extension (LTE) phase of that study. Methods: This report describes the long‐term, open‐label extension phase of a double‐blind, randomized, controlled withdrawal trial in 190 patients with JIA ages 6–17 years. Children were treated with 10 mg/kg abatacept administered intravenously every 4 weeks, with or without methotrexate. Efficacy results were based on data derived from the 153 patients who entered the open‐label LTE phase and reflect ≥21 months (589 days) of treatment. Safety results include all available open‐label data as of May 7, 2008. Results: Of the 190 enrolled patients, 153 entered the LTE. By day 589, 90%, 88%, 75%, 57%, and 39% of patients treated with abatacept during the double‐blind and LTE phases achieved responses according to the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, Pedi 70, Pedi 90, and Pedi 100 criteria for improvement, respectively. Similar response rates were observed by day 589 among patients previously treated with placebo. Among patients who had not achieved an ACR Pedi 30 response at the end of the open‐label lead‐in phase and who proceeded directly into the LTE, 73%, 64%, 46%, 18%, and 5% achieved ACR Pedi 30, Pedi 50, Pedi 70, Pedi 90, and Pedi 100 responses, respectively, by day 589 of the LTE. No cases of tuberculosis and no malignancies were reported during the LTE. Pneumonia developed in 3 patients, and multiple sclerosis developed in 1 patient. Conclusion: Abatacept provided clinically significant and durable efficacy in patients with JIA, including those who did not initially achieve an ACR Pedi 30 response during the initial 4‐month open‐label lead‐in phase.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.27431

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 240

Metadata

Authors
Ruperto, N., Lovell, D. J., Quartier, P., Paz, E., Rubio‐Pérez, N., Silva, C. A., Abud‐Mendoza, C., Burgos‐Vargas, R., Gerloni, V., Melo‐Gomes, J. A., Saad‐Magalhães, C., Chavez‐Corrales, J., Huemer, C., Kivitz, A., Blanco, F. J., Foeldvari, I., Hofer, M., Horneff, G., Huppertz, H., Job‐Deslandre, C., Loy, A., Minden, K., Punaro, M., Nunez, A. F., Sigal, L. H., Block, A. J., Nys, M., Martini, A., & Giannini, E. H.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2010-05-28
Volume
62
Issue
6
Pages
1792-1802
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2168029208
Cited by
240
References
2
FWCI
13.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.